Addressing gaps in care and insights

Dermatology conditions affect millions of patients and result in hundreds of millions of dollars in loss of productivity every year. Yet, despite increased development of new treatments, high quality research-driven insights to enable market adoption, understand safety and effectiveness profiles, broaden payer coverage, and increase access to care are lacking or have been difficult to attain.

Dermatologic conditions are complex. Accessing data shouldn’t be.

Understanding the complexities of these diseases, how they relate to other co-morbid conditions, and their impact on different patient populations requires a dynamic new approach to dermatology data curation.

Meet the largest dermatology data network in the U.S.

A comprehensive view of the patient journey from clinical development to the clinic

Bringing new treatments to market and delivering more precise care is challenging enough. Finding the data to support your programs shouldn’t be. That’s why OM1 and the American Academy of Dermatology joined forces in connecting the DataDerm™ Registry with the OM1 Real-World Data Cloud. Together, we’ve built the largest dermatology network in the U.S — rich with longitudinal clinical data and ready for addressing your most urgent questions.


Specialty clinicians


Specialty practices

Dermatology Conditions

• Acne
• Aging Skin
• Alopecia Areata
Atopic Dermatitis
Hidradenitis Suppurativa
Prurigo Nodularis
Psoriatic Arthritis

Sample conditions*

Every condition presents its own unique challenges and opportunities. Select one of our sample datasets above to explore some of the features.

AD patients with deep clinical data

7.4 yrs

Mean follow-up


Psoriasis patients with deep clinical data

7.9 yrs

Mean follow-up


Psoriatic Arthritis patients with deep clinical data

8.5 yrs

Mean follow-up


*Data counts as of Q2 2024 ©OM1 Dermatology Specialty Area

From evidence to insights

Transitioning PsO to PsA

Assess the natural course of a disease as patients gradually develop PsA in the setting of PsO


Identifying biologic eligible HS patients

Understand characteristics of the patient with HS who is a biologic responder


Treatment effectiveness by PsO subtype

Understand the role disease subtype plays in therapeutic choice (i.e. Scalp Psoriasis, Nail Psoriasis)


How we can help

Our specialized data and tools provide access to longitudinal patient journeys, and critical outcomes and endpoints, to enable rapid and more in-depth analyses.

Fully utilize deep, clinical RWD to more efficiently design and conduct clinical trials such as seeing where unmet needs are greatest or determining which groups the protocol should be designed to enroll.

Measure key safety outcomes of interest and support regulatory requirements such as monitoring and comparing the real-world safety profiles for patients on JAK Inhibitors.

Align with real world-based patient behaviors to measure adherence to novel treatment approaches such as for atopic dermatitis.

Develop sound evidence for payers through deep clinical and linked claims data for a more complete view of clinical outcomes and utilization. For example, assess the cost effectiveness of early treatment interventions for psoriatic arthritis.

RWD can help guide planning, forecasting, and improving brand performance such as understanding the size of the market by segment in PsO patient subtypes that are best aligned with a brand’s positioning.

Award-Winning Research Team

Our team of award-winning researchers have authored hundreds of publications, including scientific posters, articles in peer-reviewed journals, white papers, and books.

Request a Meeting

  • This field is for validation purposes and should be left unchanged.